HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, W R Articles by Dixon, J M Search for Related Content PubMed PubMed Citation Articles by Miller, W R Articles by Dixon, J M

Edinburgh Breast Unit Research Group, Western General Hospital, Edinburgh EH4 2XU, UK
¹ Novartis Pharma AG, Femara GBTR-Research, Oncology, K136-P65, CH-4002 Basel, Switzerland
² Novartis Pharma AG, Biostatics, Clinical Modeling and Related Technologies, WSJ-27.1.076, CH-4002 Basel, Switzerland

(Requests for offprints should be addressed to W R Miller; Email: w.r.miller{at}ed.ac.uk)

This paper was presented at the 1st Tenovus/AstraZeneca Workshop, Cardiff (2005). AstraZeneca has supported the publication of these proceedings.

Neoadjuvant endocrine treatment in which therapy is given while the primary tumour is still in the breast provides a highly useful model system by which to identify mechanisms associated with de novo resistance and signs of early acquired resistance. Most importantly, the model is clinically relevant. It has been confirmed that the absence of tumour oestrogen receptors confers resistance to endocrine therapy. Early changes in tumour cell proliferation following neoadjuvant treatment with the third-generation aromatase inhibitor, letrozole, do not predict accurately for subsequent clinical response. Additionally, changes in proliferation seen at later times can be the consequence of response and may be associated with early resistance. High expression of c-erbB2 does not reduce tumour responses to neoadjuvant treatment with aromatase inhibitors, but is associated with high tumour proliferation before and during treatment. It remains to be determined whether these characteristics confer subsequent resistance to treatment and early relapse in the adjuvant setting.

This article has been cited by other articles:

				M. J. Ellis, Y. Tao, O. Young, S. White, A. D. Proia, J. Murray, L. Renshaw, D. Faratian, J. Thomas, M. Dowsett, et al. Estrogen-Independent Proliferation Is Present in Estrogen-Receptor HER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole J. Clin. Oncol., July 1, 2006; 24(19): 3019 - 3025. [Abstract] [Full Text] [PDF]

				J M W Gee, A Howell, W J Gullick, C C Benz, R L Sutherland, R J Santen, L-A Martin, F Ciardiello, W R Miller, M Dowsett, et al. Consensus Statement Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S1 - S7. [Abstract] [Full Text] [PDF]